Cargando…

Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia

Myelodysplastic syndromes (MDS) represent a broad spectrum of diseases characterized by their clinical manifestation as one or more cytopenias, or a reduction in circulating blood cells. MDS is predominantly a disease of the elderly, with a median age in the UK of around 75. Approximately one third...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liberante, Fabio Giuseppe, Pouryahya, Tara, McMullin, Mary-Frances, Zhang, Shu-Dong, Mills, Kenneth Ian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872736/ https://www.ncbi.nlm.nih.gov/pubmed/26735888 http://dx.doi.org/10.18632/oncotarget.6773

Ejemplares similares

The histone deacetylase inhibitor Romidepsin induces as a cascade of differential gene expression and altered histone H3K9 marks in myeloid leukaemia cells
por: Clarke, Kathryn, et al.
Publicado: (2019)

Repositioning of bromocriptine for treatment of acute myeloid leukemia
por: Lara-Castillo, María Carmen, et al.
Publicado: (2016)

Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes
por: DeFronzo, Ralph A.
Publicado: (2011)

Incidence of heart valve disease in women treated with the ergot-derived dopamine agonist bromocriptine
por: Clausen, Marianne F., et al.
Publicado: (2021)

The Dopamine Agonist Bromocriptine Differentially Affects Fronto-Striatal Functional Connectivity During Working Memory
por: Wallace, Deanna L., et al.
Publicado: (2011)

310 Mechanisms of progression of myelodysplastic syndrome to fatal secondary acute myeloid leukemia
por: Chang, Daniel, et al.
Publicado: (2023)

Altered splicing and cytoplasmic levels of tRNA synthetases in SF3B1-mutant myelodysplastic syndromes as a therapeutic vulnerability
por: Liberante, Fabio Giuseppe, et al.
Publicado: (2019)

Secondary Acute Myeloid Leukemia in Myelodysplastic Syndrome Patients Aged Over 60 Years
por: Chaudhuri, Dipabali, et al.
Publicado: (2023)

Chronic Myeloid Leukaemia in The 21st Century
por: Frazer, Rachel, et al.
Publicado: (2007)

The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia
por: Karantanos, Theodoros, et al.
Publicado: (2022)

CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine
por: Karantanos, Theodoros, et al.
Publicado: (2022)

Epigenetic Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemias
por: Leone, Giuseppe, et al.
Publicado: (2008)

Immune Therapies for Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Kapoor, Sargam, et al.
Publicado: (2021)

Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic profile in type 2 diabetes
por: Tavares, G., et al.
Publicado: (2021)

Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas.
por: Missale, C., et al.
Publicado: (1995)

Myelodysplastic Syndrome/Acute Myeloid Leukemia Arising in Idiopathic Erythrocytosis
por: Langabeer, Stephen E., et al.
Publicado: (2018)

Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes and in Acute Myeloid Leukemias
por: Testa, Ugo, et al.
Publicado: (2020)

Patient-Physician Communication in Acute Myeloid Leukemia and Myelodysplastic Syndrome
por: Morelli, Emanuela, et al.
Publicado: (2021)

Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia
por: Woll, Petter S., et al.
Publicado: (2022)

Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Abaza, Yasmin, et al.
Publicado: (2022)

TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Rahmé, Ramy, et al.
Publicado: (2023)

The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia
por: Bănescu, Claudia, et al.
Publicado: (2023)

Prediction of response to bromocriptine in acromegaly.
por: Atkinson, A. B., et al.
Publicado: (1978)

Repurposing of Bromocriptine for Cancer Therapy
por: Seo, Ean-Jeong, et al.
Publicado: (2018)

Central Hyperthermia Treated with Bromocriptine
por: Natteru, P., et al.
Publicado: (2017)

The incidence, risk factors, and survival of acute myeloid leukemia secondary to myelodysplastic syndrome: A population‐based study
por: Ye, Xingnong, et al.
Publicado: (2019)

Effects of tolcapone and bromocriptine on cognitive stability and flexibility
por: Cameron, Ian G. M., et al.
Publicado: (2018)

Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes
por: Via, Michael A, et al.
Publicado: (2010)

Familial Myelodysplastic/Acute Leukemia Syndromes—Myeloid Neoplasms with Germline Predisposition
por: Baptista, Renata Lyrio Rafael, et al.
Publicado: (2017)

Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia
por: Shapiro, Roman M., et al.
Publicado: (2018)

Myelodysplastic Syndrome Progression to Acute Myeloid Leukemia at the Stem Cell Level
por: Chen, Jiahao, et al.
Publicado: (2018)

Acute Myeloid Leukemia with Basophilic Differentiation Transformed from Myelodysplastic Syndrome
por: Tanaka, Yasuhiro, et al.
Publicado: (2017)

Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2019)

p300 suppresses the transition of myelodysplastic syndromes to acute myeloid leukemia
por: Man, Na, et al.
Publicado: (2021)

Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations
por: Dutta, Sayantanee, et al.
Publicado: (2022)

Editorial: Uncovering the relationship between myelodysplastic syndromes and acute myeloid leukemia
por: Yassin, Mohamed A., et al.
Publicado: (2023)

Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia
por: Ambinder, Alexander J., et al.
Publicado: (2022)

Molecular pathogenesis of the myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2021)

Bromocriptine, a clinical and pharmacological review /
por: Thorner, Michael O.
Publicado: (1980)

Bromocriptine in type 2 diabetes mellitus
por: Shivaprasad, C., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ejjmq35m6gvi71q1rifakgrctm